Conference abstract · 4 Aug 2014
Conference abstractPublished 5 Aug 2013
A better path to biomarker validation: Using MALDI mass spec
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In industry?s quest to develop novel, targeted therapies and diagnostics, the majority of potential new products stall out in the discovery phase, never reaching the patients who could benefit. Circulating proteins provide a wealth of information, however today?s standard technologies for analyzing the serum proteome come with many drawbacks, particularly in translating biomarker knowledge into clinically useful tools. The solution can be found using a proven technique that offers practical advantages to customary methods of extracting relevant information from patients? blood: MALDI-ToF mass spectrometry (MALDI). The MALDI platform can discover unique protein signatures that identify patients likely to benefit from specific therapies, and it does not require companies to shift platforms as they move from discovery to development and commercialization. Illustrating how this can be done, Biodesix Inc. of Boulder, Colo., shares insights as one of the first companies to successfully develop MALDI into a reproducible, high-throughput tool to routinely measure protein abundance from serum samples, independent of the existence of immunoassays. The company, founded on a mission of personalizing medicine, has commercialized a serum proteomic test called VeriStrat that?s capable of predicting whether patients with advanced lung-cancer will respond to the targeted second-line therapy, erlotinib (Tarceva®). In this presentation, the audience will learn about the MALDI platform approach and how it can increase their clinical success by coordinating biomarker discovery and subsequent companion diagnostic development with drug development. This novel and practical strategy for biomarker-based diagnostic development can play a central role in the creation and commercialization of new personalized therapies.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 19 Jul 2024
Advancements and Applications of MALDI Mass Spectrometry in Personalized Medicine
Article · 27 Dec 2023
The Crucial Odyssey of Biomarker Validation: Navigating the Path to Reliable Clinical Significance
Short communication · 2019
Visual Mass-Spec Share (vMS-Share): A New Public Web-Based Mass Spectrometry Visualization and Data Mining Repository
Conference abstract · 19 Jun 2017
Discovery and validation of biomarkers for gliomas using mass spectrometry based quantitative and targeted proteomics
More from this journal
The newest in Translational Medicine.
Opinion · 25 Jun 2026
Radiomics in Translational Medicine for Quantitative Imaging and Personalized Clinical Assessment
Opinion · 25 Jun 2026
Digital Twin Technology in Translational Medicine for Individualized Disease Simulation and Clinical Planning
Opinion · 25 Jun 2026
Proteomic Signatures in Translational Medicine for Disease Stratification and Therapeutic Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalTranslational Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Mark Duncan”

